Martine Rothblatt, who serves as Chairperson and Chief Executive Officer of United Therapeutics (NASDAQ: UTHR), completed a series of stock transactions on April 1, 2026. The CEO sold a total of $5.5 million in common shares on that date, with the individual sale prices spanning from $570.8668 up to $596.1083.
In addition to the open-market sales, Rothblatt exercised stock options for 9,500 shares of United Therapeutics common stock on the same day at an exercise price of $146.03 per share. The exercise yielded a total value of $1,387,285.
Those actions were carried out pursuant to a pre-arranged 10b5-1 trading plan that Rothblatt adopted on November 7, 2025. The plan is scheduled to remain in effect until the earlier of December 31, 2026, or the exercise of 1,734,410 stock options that are set to expire on March 17, 2027.
Following the April 1 transactions, Rothblatt’s direct ownership in United Therapeutics stands at 40,513 shares. The filings also indicate indirect holdings attributed to closely held entities and family: 166 shares by Spouse; 324,518 shares by Trust; 258,117 shares by Trust; 45,596 shares by Trust; and 10,962 shares by Trust.
Market commentary included in the filings notes an InvestingPro analysis that concludes United Therapeutics currently appears overvalued relative to its Fair Value. The filing references a longer Pro Research Report for readers seeking additional valuation context and more than 14 supplementary ProTips, available through InvestingPro.
Separately, United Therapeutics has seen a string of analyst reactions after the release of TETON-1 Phase 3 clinical data for Tyvaso in idiopathic pulmonary fibrosis. H.C. Wainwright raised its price target to $660 from $600 and maintained a Buy rating, citing the trial results as a material factor in the revision.
BofA Securities increased its price target to $626 from $569 while retaining a Neutral rating, describing the TETON-1 data as a second confirmatory study for the Tyvaso indication. Jefferies also lifted its target to $733 from $668 and kept a Buy rating, noting the trial outcome exceeded expectations and raising its probability of success for the idiopathic pulmonary fibrosis indication to 95% from 75%. Jefferies additionally observed that the TETON-1 results outperformed those from the TETON-2 study conducted outside the U.S. and Canada.
In related sector news referenced in the filings, Insmed’s stock rose after Morgan Stanley upgraded the company to Overweight from Equalweight, with part of the upgrade tied to the positive clinical data reported by United Therapeutics.
The filings present a mix of insider liquidity activity and positive clinical and analyst developments. The 10b5-1 plan establishes a framework for the April 1 trades and signals that future option exercises or sales could occur under the same arrangement until the plan's termination conditions are met.
The combination of executive transactions, option exercises, third-party valuation commentary, and multiple analyst target increases frames a complex near-term picture for United Therapeutics investors. Readers seeking more granular valuation analysis are directed to the referenced InvestingPro materials cited in the filings.